Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer
Nadeem Riaz, Tyler Alban, Robert I. Haddad, Michelle Saul, Vladimir Makarov, Yingjie Zhu, Ezra E. W. Cohen, Robert L. Ferris, Peter Mu-Hsing Chang, Jin-Ching Lin, Amanda Psyrri, Prerana Bangalore Parthasarathy, Ardijana Novaj, Mruniya V. Gawali, Douglas R. Hoen, Phineas T. Hamilton, Natalie L. Silver, Ivan Jurić, Daniel G. Chawla, Ana Gradíssimo, Jennifer S. Ko, Daniel J. McGrail, Craig B. Davis, Nancy Y. Lee, Tim Chan
Topics & Concepts
AvelumabMedicineMicrobiomeCetuximabOncologyHead and neck cancerChemoradiotherapyInternal medicineImmune checkpointPembrolizumabImmune systemBlockadeTumor microenvironmentRandomized controlled trialNivolumabImmunotherapyHead and neckClinical trialImmunologyAntibodyCancerBioinformaticsEcosystemCancer researchCancer Immunotherapy and BiomarkersImmune cells in cancerInflammatory Biomarkers in Disease Prognosis